Abstract
BackgroundSimple, robust, sensitive and clinically meaningful outcome measures are required for neuroprotective trials in Parkinson's disease (PD). We explored the feasibility of a composite binary outcome measure, ‘dead or dependent’,...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have